Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.

Jean Marc PhelipJérôme DesrameJulien EdelineEmilie BarbierEric TerrebonnePierre MichelHervé PerrierLaetitia DahanVincent BourgeoisFaiza Khemissa AkouzEmilie SoularueValérie Lebrun LyYann MolinThierry LecomteFrançois GhiringhelliRomain CoriatSamy LouafiCindy NeuzilletSylvain Manfredi David Malkanull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

mFOLFIRINOX triplet chemotherapy did not meet the primary study end point. CISGEM doublet chemotherapy remains the first-line standard in advanced BTC.

Keyphrases

locally advanced
phase ii study
rectal cancer
squamous cell carcinoma
radiation therapy
papillary thyroid
open label
randomized controlled trial
chemotherapy induced
squamous cell